Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 9,592 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 9,592 shares of Tempus AI stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $566,407.60. Following the completion of the transaction, the chief executive officer directly owned 694,354 shares in the company, valued at $41,001,603.70. This trade represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ryan Fukushima also recently made the following trade(s):

• On Monday, January 5th, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The shares were sold at an average price of $64.26, for a total value of $321,300.00.
• On Monday, December 1st, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The stock was sold at an average price of $75.72, for a total value of $378,600.00.

Tempus AI Trading Down 2.7%

Shares of TEM traded down $1.59 during mid-day trading on Friday, hitting $58.37. 7,883,470 shares of the company’s stock traded hands, compared to its average volume of 5,746,147. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $10.38 billion, a P/E ratio of -49.05 and a beta of 5.22. The business’s 50-day moving average price is $62.60 and its 200-day moving average price is $73.38. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. dropped their price target on Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Needham & Company LLC boosted their target price on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. HC Wainwright decreased their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Morgan Stanley boosted their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Finally, Robert W. Baird started coverage on shares of Tempus AI in a report on Tuesday. They issued an “outperform” rating and a $59.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $85.92.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently bought and sold shares of TEM. Cranbrook Wealth Management LLC bought a new position in shares of Tempus AI during the 3rd quarter valued at about $25,000. JPL Wealth Management LLC bought a new stake in Tempus AI in the 3rd quarter worth approximately $26,000. Los Angeles Capital Management LLC bought a new position in shares of Tempus AI during the 4th quarter valued at approximately $27,000. GAMMA Investing LLC purchased a new position in shares of Tempus AI in the third quarter valued at $28,000. Finally, Allworth Financial LP raised its stake in Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares in the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.